RE:pretty much as expected RazeKreations wrote: Today's investors update went pretty much as expected. Cameron was a little limited on how things are progressing because of fiscal year end report looming. They will be going into blackout period very shortly. Kinlytic opportunities are improving, that was one of the best little bits of information gained. They did explain why the update was so close to year end report and it was because of conflicts with travel and scheduling. He reported that there are 10 scientist working on developing new products. 100 employee's hired plus 10 contracted Lots of little bits of information on new opportunities and collaborations. Should have a better understanding of progress when fiscal year end report is posted. Then the webinar after that will bring much more insight into the company
Generally I agree, although I am bracing for a
slightly slower uptick in new (QAP) order growth than originally might have been expected. As Cameron mentioned, sales cycles can be long in Life Sciences.
PCR testing (and therefore VTM need) in ON currently at about 8000/day (250k/month). They are "in discussions" to secure commitments for a large share of ON needs and in the future perhaps 1/4 to 1/2 of Cdn needs in the future. But all Governments, as we all know, move at a snails pace.
At the end of the day, every stocks's true value is a function of long term cash flow generation prospects, discounted to today. Worst case, IMO, is we get a small delay on Sales/cash flow uptick (by as much as a few Qtrs). That would barely impact LT discounted cash flows...unless there was some evidence that new customers didn't want their product (no indication of quality concerns that I can see)
Bought some more yesterday at .45. More patience required, with perhaps a ST surprise on Kinlytic (although we've been waiting on that for years)
MM